Paritaprevir - monotherapy

Drug Profile

Paritaprevir - monotherapy

Alternative Names: ABT-450; Veruprevir; Veruprevir anhydrous

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer Abbott Laboratories; Enanta Pharmaceuticals
  • Class Antivirals; Aza compounds; Cyclopropanes; Phenanthridines; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 17 Feb 2017 AbbVie has patent protection for paritaprevir in USA (AbbVie 10-K form, February 2017)
  • 25 Sep 2014 Biomarkers information updated
  • 30 Jun 2010 Abbott completes a phase I trial in healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top